Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2…
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE…
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug…
LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic…
VAN NUYS, Calif.--(BUSINESS WIRE)--The Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System…
The Princess Royal was introduced to the first FDA-cleared portable MR brain imaging system being used to test the disparities…
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month ---- Study will evaluate the use…
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for…
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…
The Canadian startup has gained exclusive access to the U.S. accelerator, including funding, resources, and engagement with world-renowned health organizationsTORONTO--(BUSINESS…